Autonomix Secures Third U.S. Patent, Broadening Neuromodulation IP Portfolio
AMIX is trading near its 52-week low of $3.98 (6.8% below the low) on light trading volume (0.2× avg).
Summary
Autonomix Medical has been granted U.S. Patent No. 12,471,776 for ANS assessment systems, kits, and methods, expanding its intellectual property around autonomic nervous system monitoring. This is the third patent announced in recent months, following grants in May and July for related but distinct technologies. The new patent covers physiologic signal monitoring to assess sympathetic and parasympathetic function, potentially supporting patient selection and procedural guidance. While the company remains pre-revenue with a going concern warning and a recent reverse split, the growing patent estate strengthens its technology platform and could enhance its competitive position in the neuromodulation space. The stock trades near its 52-week low, and this IP milestone may provide some positive momentum.
At the time of this announcement, AMIX was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $3.98 to $36.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.